Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up

Stopped early

Conditions studied: Lung Cancer, NSCLC, Lung Adenocarcinoma

In brief

This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006).This registry is specific to Surgeons (ONC003). Outcomes measures on lung cancer relapse and death from any cause will be collected.

Key facts

Study ID

NCT02121925

Run by

Myriad Genetic Laboratories, Inc.

People needed

227

Starts

2014-05-01

Expected to finish

2017-07-31

Last updated by the study team

2017-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of early stage non-small cell lung adenocarcinoma
• Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the investigational site
• Resection of tumor within previous 2 months of enrollment
• ECOG performance of 0-2
• A minimum life expectancy of six months

You may not qualify if…

• Pre-operative radiation or chemotherapy for NSCLC
• Post-operative radiation or chemotherapy for NSCLC
• Enrollment in a separate clinical trial restricting treatment options
• Unable to provide informed consent

Where it is running

• Study site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.